Insilico Medicine to Present First-in-Human Phase 1 Data for AI-Designed Pan-TEAD Inhibitor ISM6331 at ESMO 2026
核心洞察
Insilico Medicine (搜索)'s AI-designed pan-TEAD (搜索) inhibitor ISM6331 has been accepted for a Rapid Oral presentation at the ESMO Congress 2026 in Madrid, Spain.
The presentation will feature first-in-human Phase 1 results evaluating safety, tolerability, and preliminary efficacy in patients with mesothelioma (搜索) and other advanced solid tumors (搜索).
ISM6331 targets TEAD (搜索) transcription factors in the Hippo signaling pathway, a critical regulator of cell proliferation and therapeutic resistance across multiple solid tumors.
Insilico Medicine (搜索), a clinical-stage generative AI-driven drug discovery company, announced that first-in-human Phase 1 trial data for ISM6331 has been accepted for a Rapid Oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain. ISM6331 is a novel, AI-designed pan-TEAD (搜索) inhibitor targeting the Hippo signaling pathway, and the presentation marks a significant clinical milestone for the molecule.
"TEAD (搜索) has long been recognized as an attractive target in hard-to-treat solid tumors, but small-molecule inhibition has historically posed significant design challenges," said Feng Ren, Ph.D., Co-CEO and Chief Scientific Officer of Insilico Medicine (搜索). "The selection of ISM6331 for a Rapid Oral presentation at ESMO 2026 highlights the potential of our AI-generated platform to target complex oncogenic drivers like the Hippo pathway and represents a promising pan-TEAD approach that we are eager to share with the community."
Presentation Details
The Rapid Oral presentation, designated Abstract #997, will take place on Sunday, October 25, 2026, from 08:30 to 10:00 in the Cordoba Auditorium – Hall 4, as part of the Developmental Therapeutic session. The presentation is titled "First-in-human Multicenter Phase 1 Study of ISM6331, an AI-Designed Pan-TEAD (搜索) Inhibitor, in Patients with Mesothelioma (搜索) or Other Advanced Solid Tumors (搜索)."
Clinical Development and Rationale
ISM6331 is being evaluated in a global, multicenter Phase 1 clinical trial enrolling patients with malignant mesothelioma (搜索) and other advanced solid tumors (搜索). The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of ISM6331, with the goal of informing continued clinical development strategies.
"Presenting our first-in-human Phase 1 study at ESMO marks an important clinical milestone for ISM6331," said Halle Zhang, Ph.D., Vice President, Clinical Development – Oncology at Insilico Medicine (搜索). "Patients with advanced mesothelioma (搜索) and other Hippo-driven solid tumors face limited therapeutic options. These preliminary clinical findings provide early encouragement as we evaluate ISM6331's safety, pharmacokinetics, and initial antitumor activity to inform our ongoing clinical development strategies."
Mechanism of Action and AI-Driven Discovery
ISM6331 is a potent, small-molecule pan-TEAD (搜索) inhibitor discovered and designed using Insilico Medicine (搜索)'s proprietary generative AI-powered drug discovery platform, Chemistry42. The molecule targets TEAD transcription factors, which serve as the principal downstream effectors of the Hippo signaling pathway—a critical regulator of cell proliferation, survival, tissue homeostasis, and therapeutic resistance across a broad range of solid tumors.
Although the Hippo pathway has long been recognized as a promising therapeutic target in oncology, developing effective small-molecule TEAD (搜索) inhibitors has remained a significant medicinal chemistry challenge. ISM6331 was designed to selectively inhibit pan-TEAD activity, addressing an area of high unmet medical need for patients with Hippo-driven malignancies.